Aligos Therapeutics (ALGS)

Executive Summary

Aligos Therapeutics is a clinical-stage biotechnology company focused on developing antiviral therapies for chronic hepatitis B (CHB), COVID-19, and NASH/MASH. Founded in 2018 and headquartered in South San Francisco, the company leverages its expertise in medicinal chemistry and biology to advance a pipeline of small molecules and oligonucleotide therapies. Aligos' lead asset, ALG-000184, is a capsid assembly modulator for CHB currently in Phase 2 trials. The company is also evaluating ALG-055343, a THR-β agonist for MASH, which recently completed a Phase 1 study with encouraging safety and pharmacokinetic data. With a market cap of approximately $38 million, Aligos represents a high-risk, high-reward opportunity driven by upcoming clinical milestones. The company's financial runway extends through 2026, supported by cost discipline and potential non-dilutive funding. However, the stock faces volatility due to early-stage pipeline risk and limited near-term revenue.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data for ALG-000184 in chronic hepatitis B60% success
• H2 2026Phase 2a initiation or interim data for ALG-055343 in MASH50% success
• Q4 2026Regulatory update or partnership for COVID-19 antiviral program30% success